Compounds and methods for kinase modulation, and indications therefor

Patent metadata

Field	Value
Publication number	US-12076322-B2
Application number	US-202217895972-A
Country	US
Kind code	B2
Filing date	Aug 25, 2022
Priority date	Feb 7, 2011
Publication date	Sep 3, 2024
Grant date	Sep 3, 2024

Abstract

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

First claim

What is claimed is:

1. A method for treating a subject with a B-Raf mediated disease or condition, said method comprising administering to said subject an effective amount of a compound of formula:

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
each R 11 is independently halogen;
Q is H or F; and
m is 0, 1, or 2;
wherein the B-Raf mediated disease or condition is glioma.

2. The method of claim 1 , wherein R 11 is fluoro.

3. The method of claim 1 , wherein Q is H.

4. The method of claim 1 , wherein Q is fluoro.

5. The method of claim 1 , wherein m is 0.

6. The method of claim 1 , wherein m is 1.

7. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignees

• Plexxikon Inc

Inventors

• Ibrahim Prabha N
• Zhang Chao
• Spevak Wayne
• Zhang Jiazhong
• Wu Guoxian
• Lin Jack
• Cho Hanna
• Nespi Marika
• Shi Songyuan
• Ewing Todd
• Zhang Ying

Classifications

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• A61K31/407

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title